News
-
Danish inhaled drug developer Serendex has announced that it has met a number of milestones this year in preparation for clinical development of its portfolio. According to Serendex, in the first quarter of 2015, the… Read more . . .
-
Inhaled drug developer Prosonix will be acquired by Circassia Pharmaceuticals for a total of £100 million in cash, the company said. Of that total, £70 million will be paid up front, with an additional £30… Read more . . .
-
Discovery Laboratories has announced that data from a Phase 2a clinical trial of Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome (RDS) in premature infants show that the novel delivery technology performed… Read more . . .
-
In a note accompanying a set of articles on the impact of the FDA’s ban on the use of CFC propellants in metered dose inhalers and the transition to HFA inhalers, published online on May… Read more . . .
-
Pharmaxis has announced that beginning in June 2015, Chiesi Farmaceutici will take over the commercialization of the Bronchitol mannitol DPI for the treatment of cystic fibrosis in the UK, Ireland, and Germany. Additionally, Pharmaxis said… Read more . . .
-
Actavis has announced that it is relaunching 0.25 and 0.5 mg vials of budesonide inhalation suspension, a generic version of AstraZeneca’s Pulmicort Respules, after the United States Court of Appeals for the Federal Circuit lifted… Read more . . .
-
Pennsylvania-based Egalet Corporation has announced that it will begin promoting Sprix ketorolac tromethamine nasal spray in the second quarter of 2015. Sprix is a non-steroidal anti-inflammatory drug (NSAID) for the short-term treatment of moderate to… Read more . . .
-
Timer Designs, a Dutch company specializing in compliance devices, has introduced a new version of its Compliance Cradle for Breo Ellipta, which GSK will supply with the inhaler, the company said. The cradle uses an… Read more . . .
-
Capsugel has announced that Bend Research, which Capsugel acquired in September 2013, has manufactured Phase 2 clinical trial supplies of a DPI formulation, its first inhalation product manufactured at that scale. The biopharmaceutical formulation was… Read more . . .
-
Advanced Inhalation Therapies (AIT) has announced that its AIT-CF high dose inhaled formulation of nitric oxide (NO) for the treatment of cystic fibrosis has been granted orphan medical product designation by the European Commission. In… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.